as 11-14-2024 3:31pm EST
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
Founded: | 2010 | Country: | United States |
Employees: | N/A | City: | SAN DIEGO |
Market Cap: | 127.1M | IPO Year: | 2017 |
Target Price: | $22.83 | AVG Volume (30 days): | 146.1K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -21.30 | EPS Growth: | N/A |
52 Week Low/High: | $2.86 - $23.18 | Next Earning Date: | 11-07-2024 |
Revenue: | $4,152,999 | Revenue Growth: | 449.34% |
Revenue Growth (this year): | 36.93% | Revenue Growth (next year): | 236.45% |
CBUS Breaking Stock News: Dive into CBUS Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
GuruFocus.com
5 days ago
Simply Wall St.
5 days ago
GlobeNewswire
7 days ago
GuruFocus.com
9 days ago
GlobeNewswire
10 days ago
GlobeNewswire
22 days ago
GlobeNewswire
25 days ago
The information presented on this page, "CBUS Cibus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.